. Small cargo proteins and large aggregates can traverse the golgi by a common mechanism without leaving the lumen of cisternae.
SUPPLEMENT 1. Problem-Sets that were given to students as worksheet handouts. These 4 problemsets (Cystic Fibrosis, Cell Cycle, RTK Signaling, BRCA Tumors) were the focus of analysis in the paper.
CYSTIC FIBROSIS
Cystic Fibrosis (CF) is a genetic disorder that results from a mutation in an ion channel termed CFTR. The lung is one of the organs most affected by the disease. Thick mucus builds up on the surface of alveolar cells in the lung and patients are plagued with frequent lung infections. In individuals who do not have CF, CFTR allows chloride ions to flow from the inside of lung cells to the extracellular space. Extracellular chloride concentrations are high, relative to intracellular, as are extracellular sodium concentrations; intracellular potassium concentrations are high. At the steady state, water diffusion maintains an appropriately fluid mucus lining of the alveolar space. The most common CF-causing mutation (F508) results in a mis-folded protein that is not properly modified in the Golgi, is degraded by the cell, and is almost absent from the cell surface. The biological model depicts the alveolar space in normal and diseased lungs. The current CF model includes increased levels of a sodium channel (ENaC) at the surface of lung cells when CFTR is missing from the cell surface. This misregulation of ENaC further exacerbates the salt and water balance in patient's lungs. The following experiments, from research over a number of years, have contributed to this model of CF disease.
Q1: Given what you know about typical membrane potentials and the chemistry of ions behavior, why does sodium flow in the direction shown in the model? Q2: Based on the biological model, how would you predict that the intracellular concentration of Cl -and Na + would be different in normal and CF patient lung cells? How do you predict this difference would affect the net diffusion of water between the mucus and the intracellular environment?
In Experiment 1 (Boucher, Cotton, Gatzy, Knowles, & Yankaskas, 1988) , airway cells were collected from normal and CF patients and cultured. A microelectrode was used to measure potential differences (Va) across the membranes of individual cells (similar to Patch Clamp analysis). Panel 1 is a representative example of the trace from a single sample for which the membrane potential was measured in a control solution (Ringer) and then after the introduction of a chemical that specifically inhibits ion flow through sodium channels (Amiloride).
Q4: What is your interpretation of the sample data shown when cells are treated with Amiloride? What factors in the biological model could account for how each tissue responds to this drug?
In Experiment 2 (Yan, Samaha, Ramkumar, Kleyman, & Rubenstein, 2004) 
CELL CYCLE
This worksheet is based on work by Evans and Rosenthal et al. (1983) and Murray, Solomon and Kirschner (1989) (Evans, Rosenthal, Youngblom, Distel, & Hunt, 1983; Murray, Solomon, & Kirschner, 1989) . The first set of data were obtained from dividing sea urchin eggs, when scientists had relatively little idea about what causes cells to progress through the cell cycle. The second set of data were obtained from a xenopus egg extract system. At the time of the second paper, scientists were hypothesizing the role of cyclin as a regulatory component of maturation promoting factor. At the point this paper was published, scientists were trying to functionally explain the exit of cells from mitosis using what they knew about MPF.
Biological Model (Gautier et al., 1990) . Diagram of the cdc2/Cyclin Cycle. This simplified diagram illustrates the essentials of the relationship between cyclin, cdc2, kinase activity and the cellular consequences of that activity. Newly synthesized cyclin joins preexisting cdc2 to form pre-MPF, which lack kinase activity until the cdc2 subunit is dephosphorylated. Cyclin is phosphorylated as the cdc2 becomes active and active MPF is then able to initiate entry into mitosis. Cyclin is subsequently destroyed. This leads to loss of MPF activity and return to interphase. Figure 2 . These experiments were performed by adding sperm nuclei to oocyte extracts as an artificial system to measure movement of the nuclei between mitosis and interphase. mRNA for the cyclin protein was added to the system to allow synthesis of cyclin proteins. The cylin mRNA was either for a version similar to wild-type (CYC wild type) or for a mutant version of the protein that was not able to be cleaved by proteolysis (CYCdelta90). Radiolabled-methionine was also added, so that when cyclin proteins were made they could be detected when run on gel. The times shown were minutes after the extracts were combined with the nuclei. The indicator of artificial entry into mitosis was measured by watching nuclear break down (NBD). Return of nuclei to an interphase-like state was also observed (Inter). 
RTK SIGNALLING
This model (Lavoie & Therrien, 2011) depicts how a mutant form of B-RAF can activate MEK and thus ERK, leading to cellular proliferation, even in the absence of signaling through RAS. The model zooms into a portion of the RTK pathway (some parts are not shown). Prior to the research shown here, scientists had shown that mutations in RAS were common in malignant tumors and that this was because constitutively active RAS could lead to signaling events that promoted unregulated cellular proliferation. The authors of the data figures below (Davies et al., 2002 ) are trying to demonstrate that mutations in B-RAF can also contribute to the development of cancer, independent of mutations in RAS.
The results in Table 1 show a screen of samples taken from various human tumors. Each line shows a different mutation found in the B-RAF gene. "Mel." and "Mel STC" are two forms of melanoma. "Colo. ca." is colorectal cancer. Table 1 ? How do they support the idea that B-RAF is a clinically important oncogene? [some columns, from other types of samples, are deleted for simplicity] Figure 1 . In this experiment, B-RAF protein was isolated and combined with additional proteins in vitro. The level of activation of MEK in vitro was then measured. B-RAF is the wild type version of the protein. G463V, G468A, L596V and V599E are four different B-RAF mutants. Fold activation is determined by dividing the level of activation measured by the level measured for the control (BRAF). Thus it represents the "fold" increase over baseline. In a prior experiment, 89% of the mutations found in the cancer cells were within or very close to the activation segment of B-RAF, which is responsible for its protein kinase activity. Each of the mutants represented in this figure were from mutations found in the kinase domain of the protein. Western blots were performed with antibodies that specifically bind to phosphorylated ERK proteins (ERK1/2) (the antibody does not bind to the ERK protein if it is not phosphorylated). Figure 2 Q5. Explain how these results relate to the biological model. 
Q1. What can you conclude from the data in

Q4. Describe and interpret the results of the experiment performed in
BRCA TUMORS
This model (Bryant et al., 2005) above explains why BRCA2 -/-tumors are thought to respond to PARP inhibitors. PARP is a normal cellular protein that is required for repair of single stranded break in DNA (something that happens all the time in cells). There are actually two PARP proteins referred to in this paper PARP1 and PARP 2. The authors' model suggest that PARP1 is the protein important here. In this model PARP inhibition is accomplished through treatment with specific drugs. The collapsed replication fork is thought to form when single stranded breaks cannot be repaired. The collapsed replication fork includes a double stranded break in DNA. Normally, these double stranded breaks can be repaired through another mechanism (homologous recombination error-free). This mechanism does not function properly in BCRA-/-cells. Thus BRCA-/-cells do not have an efficient way to repair these double stranded breaks. Data figures are from a published article (Bryant et al., 2005) . RT-PCR for BRCA2, PARP1, PARP2, and -actin was performed on mRNA collected from these cells (panel A). In a separate set of experiments, cancer cells treated with siRNA (as in panel a) were followed for 48 hours after siRNA treatment and survival rate was measured. Makes an inference about some aspect of the figure   1 Contains none of the listed points Does not move past a literal description of the figure/data Listed points for "Cystic Fibrosis" Problem Set Fig.1 • There is a greater drop in CF cells treated with Amiloride because CF cells have more Na channels that can be affected by the Amiloride treatment (more channels = bigger affect).  Amiloride treatment makes both normal and CF cells more negative than before Amiloride treatment because less positive ions are flowing in, making the inside of the cell more negative. Fig.2 • Cl-flow through Cl channels decreases cell surface levels of ENaC without affecting total levels of ENaC.
 Cl-flow either directly or indirectly inhibits ENaC from reaching the cell surface or removes it from the cell surface, but does NOT inhibit synthesis/expression of ENaC.
Listed points for "Cell Cycle" Problem Set (This problem set presented in the Supplementary Figure has been revised by the instructor since the data were collected for this study. The version presented here is the one currently used by the instructor. Figure 1 in the original version is the same as Figure 2 in the current version. Figure 2 here is no longer present in the current version, but can be found in Murray, Solomon, & Kirschner, 1989) . Fig.1 • WT cyclin is degraded before interphase while cycΔ90 (nondegradable cyclin) inhibits entry into interphase.  Cyclin must be degraded to enter interphase or to exit mitosis (or to deactivate the MPF).  As long as some amount of cyclin is present, regardless if some gets degraded, the cell cannot enter interphase. (Students may equate this to: nondegradable cyclin is the "dominant" phenotype or overcomes the degradable cyclin phenotype). Fig.2 • Cells with cycΔ90 are stalled in mitosis (specifically prophase).
 Cells with cycΔ90 cannot enter interphase to continue the cell cycle and divide/cleave, hence why there is still only one cell (one nuclei). Alternatively, cells with WT cyclin can degrade the cyclin and enter interphase to continue the cell cycle and divide, hence why there are 14 nuclei. Or some mechanism for why cell cannot enter interphase mentioned.
Listed points for "RTK Signaling" Problem Set Fig.1 • BRAF mutants have higher MEK activation compared to WT.  BRAF mutants can activate the downstream signaling cascade more than WT to increase cell proliferation and survival (supporting that BRAF is an oncogene). Fig.2 • In WT, ERK is phosphorylated only in the presence of HRAS because active RAS phosphorylates BRAF which phosphorylates MEK which phosphorylates ERK.  Some BRAF mutants activate ERK in the absence of HRAS.
Listed points for "BRCA Tumors" Problem Set Fig.1 • BRCA deficient cells are more sensitive to PARP inhibition (die quicker at lower doses of drug).
 The phenotype can be rescued to wild-type condition by complementing BRCA back in.  Cells without both DNA repair mechanisms (BRCA and PARP) will die because there is no back-up mechanism to repair DNA. Fig.3 • In B, treatment with the PARP inhibitors causes more double stranded breaks for both BRCA + or -cell types (because you need PARP to fix double stranded breaks).  In C, BRCA deficient cells are not able to repair double stranded breaks. Cells with BRCA are able to repair double stranded breaks.  Cells without both BRCA and PARP will have DNA damage that they cannot repair because there is no backup mechanism to repair. Fig.4 • Thigh circumference decreases after PARP inhibition drug treatment ONLY in the BRCA deficient mice.
 When the thigh circumference decreases in BRCA deficient mice, the tumor is shrinking because the tumor cell are dying because they have no back-up mechanism to repair their DNA when PARP is inhibited.
